Properties
What is it?
International Nonproprietary Name - zuclopenthixol Clinical-pharmacological group: Central Nervous System → Psychotropic agents → Neuroleptic (antipsychotic) agents Composition Clear, yellow, oily injection solution 200mg/ml or 500 mg/ml in 1 ml ampoules, containing 200 or 500 mg of zuclopenthixol decanoate in vegetable oil. Indications Acute and chronic schizophrenia and other psychotic disorders, especially with hallucinations, paranoid delusions, and disorders of consciousness, as well as in agitated states, increased restlessness, and aggressiveness. Dosage and administration Clopixol Depot is administered by deep intramuscular injection into the gluteal region in the upper outer quadrant (locally easily absorbed). The interval between injections and dosage should be determined individually according to the patient's condition. Clopixol Depot 200mg/ml: For maintenance therapy, the dosage range is usually 200-400 mg (1-2 ml) every 2-4 weeks. Some patients may require higher doses or shorter intervals between injections. If the volume of the intramuscular solution (200 mg/ml) exceeds 2-3 ml, it is preferable to use a higher concentration solution (Clopixol Depot 500 mg/ml). Clopixol Depot 500 mg/ml: Usually administered 250-750 mg (0.5-1.5 ml) every 1-4 weeks. When switching from oral treatment with Clopixol or Clopixol-Acupas to maintenance therapy with Clopixol Depot, follow the scheme below: When switching from oral Clopixol to intramuscular Clopixol Depot: Daily oral dose of Clopixol (mg) X 8 = intramuscular Clopixol Depot (mg) every 2 weeks. Patients should continue to take oral Clopixol during the first week after injection, but at a reduced dose. Switching from intramuscular Clopixol-Acupas to intramuscular Clopixol Depot: Intramuscular Clopixol Depot 200-400 mg (1-2 ml) should be administered simultaneously with the last injection of Clopixol-Acupas. Repeat injections of Clopixol Depot should be given every 2 weeks. Higher doses or shorter intervals between injections may be used if necessary. Side effects Nervous system. Extrapyramidal symptoms may develop, especially in the initial stage of treatment. In most cases, they are corrected by reducing the dose and/or prescribing antiparkinsonian drugs. However, regular prophylactic use of these drugs is not recommended. In rare cases, with long-term therapy, the patient may develop tardive dyskinesia. Antiparkinsonian drugs do not eliminate its symptoms. Dose reduction is recommended, or if possible, discontinuation of therapy. Mental effects. Drowsiness in the initial stage. Autonomic nervous system and cardiovascular system. Dryness of the mouth, accommodation disturbances, urinary retention, constipation, tachycardia, orthostatic hypotension, and dizziness. Liver. Minor changes in liver tests are rarely observed. Contraindications Acute poisoning with alcohol, barbiturates, and opiates; comatose state. Precautions: Clopixol-Depot should be prescribed with caution to patients with convulsive syndrome, chronic hepatitis, and cardiovascular diseases. During long-term therapy, especially if treatment is with high doses, it is necessary to monitor the patient's condition and periodically assess their condition to decide on dose reduction. Clopixol may affect the ability to drive a car and operate other machinery. Therefore, caution is necessary at the beginning of therapy until the patient's response to treatment is determined. During long-term therapy, detailed monitoring of the patient's condition is necessary. Prescription of Clopixol is not recommended during pregnancy and breastfeeding.